Morningstar

bluebird bio Inc BLUE

Morningstar Rating

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Business Wire Sep 27, 2024 8:30pm
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

Business Wire Sep 24, 2024 11:00am
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

Business Wire Sep 13, 2024 8:41pm
bluebird bio Announces September Investor Events

Business Wire Aug 28, 2024 12:00pm
bluebird bio Announces Receipt of Expected Notices from Nasdaq

Business Wire Aug 23, 2024 8:05pm
bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Business Wire Aug 14, 2024 11:00am
bluebird bio Announces Second Quarter 2024 Results Call Date

Business Wire Aug 12, 2024 12:00pm
bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire Aug 2, 2024 8:05pm
BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GlobeNewswire Jul 13, 2024 1:00am
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment

MarketWatch Dec 9, 2023 12:47pm
Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment

Global News Select Dec 8, 2023 8:56pm
Bluebird Bio Gets FDA OK of Lyfgenia Gene Therapy in Sickle-Cell Disease

Global News Select Dec 8, 2023 4:48pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.